Related Experiment Video
Updated: Jul 14, 2026
07:51
Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface
Published on: May 21, 2015
Paternal leukocyte immunization in primary recurrent spontaneous aborters
A M Bahar1, A G White, I H Al-Abdullah
1Department of Obstetrics and Gynecology and Department of Organ Transplantation, Faculty of Medicine, University of Kuwait, Kuwait.
Annals of Saudi Medicine
|March 1, 1993
Summary
Paternal leukocyte immunization may improve pregnancy outcomes for women with recurrent abortions. Development of mixed lymphocyte reaction (MLR) blocking antibodies post-immunization is a strong indicator of successful pregnancy. Lymphocytotoxic antibodies showed less significant results.
Area of Science:
- Immunology
- Reproductive Medicine
- Obstetrics
Background:
- Recurrent spontaneous abortions (RSA) pose a significant challenge in reproductive medicine.
- The role of immune factors, including human lymphocyte antigen (HLA) and antibodies, in pregnancy maintenance is under investigation.
- Paternal leukocyte immunization is a potential therapeutic strategy for unexplained RSA.
Purpose of the Study:
- To investigate the roles of lymphocytotoxic antibodies and maternal antipaternal mixed lymphocyte reaction (MLR) blocking antibodies in pregnancy maintenance.
- To assess the efficacy of paternal leukocyte immunization in patients with recurrent abortions.
- To determine if antibody seroconversion post-immunization correlates with successful pregnancy outcomes.
Main Methods:
- A pilot study involving 36 patients with unexplained, first-trimester, primary recurrent spontaneous abortions.
- Detection of lymphocytotoxic and MLR blocking antibodies before and after paternal leukocyte immunization in 26 women lacking these antibodies.
- Analysis of pregnancy outcomes (successful pregnancy vs. re-abortion) in relation to antibody development.
Main Results:
- A 43.3% discordance rate was observed between lymphocytotoxic and MLR blocking antibodies.
- Post-immunization, seroconversion rates were 50% for lymphocytotoxic antibodies and 61.5% for MLR blocking antibodies.
- Patients developing MLR blocking antibodies post-immunization had an 83.3% success rate, significantly higher than those who did not seroconvert (P<.05).
Conclusions:
- Development of maternal antipaternal MLR blocking antibodies following paternal leukocyte immunization is a significant indicator of successful pregnancy in patients with recurrent abortions.
- Lymphocytotoxic antibodies appear to be a less reliable predictor of pregnancy success compared to MLR blocking antibodies.
- Paternal leukocyte immunization may be a viable strategy for improving pregnancy outcomes in selected patients with recurrent abortions.
